Compare HLIO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | VRDN |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 1996 | 2014 |
| Metric | HLIO | VRDN |
|---|---|---|
| Price | $80.77 | $17.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $66.17 | $35.46 |
| AVG Volume (30 Days) | 381.5K | ★ 2.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $200,727,000.00 | $5,706,000.00 |
| Revenue This Year | $3.67 | $13.73 |
| Revenue Next Year | $5.00 | $279.00 |
| P/E Ratio | $137.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.95 | $13.18 |
| 52 Week High | $95.05 | $34.29 |
| Indicator | HLIO | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 47.55 |
| Support Level | $78.79 | $15.58 |
| Resistance Level | $86.74 | $18.05 |
| Average True Range (ATR) | 3.18 | 0.91 |
| MACD | -0.68 | -0.17 |
| Stochastic Oscillator | 25.06 | 11.98 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.